Gepotidacin, a novel triazaacenaphthylene antibacterial agent, is the first in a 
new class of type IIA topoisomerase inhibitors with activity against many 
biothreat and conventional pathogens, including Neisseria gonorrhoeae To assist 
ongoing clinical studies of gepotidacin to treat gonorrhea, a multilaboratory 
quality assurance investigation determined the reference organism (N. 
gonorrhoeae ATCC 49226) quality control MIC range to be 0.25 to 1 μg/ml (88.8% 
of gepotidacin MIC results at the 0.5 μg/ml mode).